Chicharro P, Rodríguez-Jiménez P, Capusan T M, Herrero-Moyano M, de Argila D
Servicio de Dermatología, Hospital Universitario de La Princesa, Madrid, España.
Servicio de Dermatología, Hospital Universitario de La Princesa, Madrid, España.
Actas Dermosifiliogr (Engl Ed). 2018 Dec;109(10):888-892. doi: 10.1016/j.ad.2018.06.005. Epub 2018 Sep 8.
Solar urticaria is an uncommon photodermatosis. First-line treatment is with antihistamines; second-line treatment includes induction of light tolerance using UV phototherapy.
We aimed to describe and evaluate the effectiveness of a desensitization protocol with narrowband UV-B in patients with solar urticaria.
We performed a retrospective study of patients with solar urticaria with an action spectrum in the UV-A range, the visible light range, or both who had received therapy with narrowband UV-B for induction of light tolerance. Short courses of treatment were administered (<20 sessions, 3 per week) during spring. The initial dose was determined according to the skin type. The Skindex-29 was administered before treatment and after summer; a nonvalidated questionnaire was also administered after summer to evaluate disease activity and satisfaction with treatment.
We included 8 patients with an action spectrum (4 with visible light and 4 with UVA plus visible light). Seventeen courses (1-6 per patient) were administered per year. The number of sessions per year ranged from 11 to 20. The mean dose of narrowband UV-B per course was 7.45J/cm. No patients experienced flares or adverse effects during treatment. The response was satisfactory in 6 patients. The improvement in the overall Skindex-29 score was greater than 20% in 78.6% of cases. The improvement in the function and symptoms subscales was over 20% in 71% and 64% of cases, respectively.
Induction of light tolerance with narrowband UV-B in solar urticaria is safe and effective in a high percentage of patients.
日光性荨麻疹是一种罕见的光皮肤病。一线治疗是使用抗组胺药;二线治疗包括使用紫外线光疗诱导光耐受性。
我们旨在描述和评估窄谱中波紫外线脱敏方案对日光性荨麻疹患者的有效性。
我们对具有紫外线A范围、可见光范围或两者兼有的作用光谱且接受窄谱中波紫外线治疗以诱导光耐受性的日光性荨麻疹患者进行了回顾性研究。在春季进行短疗程治疗(<20次,每周3次)。初始剂量根据皮肤类型确定。在治疗前和夏季后使用Skindex-29;夏季后还使用一份未经验证的问卷来评估疾病活动度和对治疗的满意度。
我们纳入了8例具有作用光谱的患者(4例为可见光,4例为紫外线A加可见光)。每年进行17个疗程(每位患者1 - 6个疗程)。每年的疗程数为11至20个。每个疗程窄谱中波紫外线的平均剂量为7.45J/cm²。治疗期间没有患者出现皮疹发作或不良反应。6例患者的反应令人满意。78.6%的病例中Skindex-29总分改善超过20%。功能和症状子量表的改善分别在71%和64%的病例中超过20%。
窄谱中波紫外线诱导日光性荨麻疹患者的光耐受性在高比例患者中是安全有效的。